Factors contributing to compliance with osteoporosis medication

Israel Medical Association Journal

Volumn 10, Issue 3, 2008, Pages 207-213

  Kertes, Jenny ^a,b   Dushenat, Marina ^a   Vesterman, Jinny Landes ^a   Lemberger, John ^a   Bregman, Joseph ^a   Friedman, Nurit ^a  

^a MACCABI HEALTHCARE SERVICES   (Israel)

^b Dept of Research and Evaluation of Health Services ^*  (Israel)

Author keywords

Bisphosphonates; Medication compliance; Osteoporosis; Prevention; Women

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RALOXIFENE; RISEDRONIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HEALTH CARE MANAGEMENT; HEALTH CARE ORGANIZATION; HEALTH MAINTENANCE ORGANIZATION; HUMAN; IMMIGRANT; ISRAEL; MAJOR CLINICAL STUDY; NATIONAL HEALTH INSURANCE; OSTEOPOROSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT PERSISTENCE; PENSION; RECOMMENDED DRUG DOSE; SOCIAL STATUS; TREATMENT DURATION;

AGED; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DATABASES, FACTUAL; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; ISRAEL; MIDDLE AGED; OSTEOPOROSIS; PATIENT COMPLIANCE; SOCIOECONOMIC FACTORS;

EID: 43249104480     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(10 suppl):s1-34.
2. Ettinger MP. Aging bone and osteoporosis. Arch Intern Med 2003;163:2237-46.
3. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22.
4. Raisz LG. Screening for osteoporosis. N Engl J Med 2005; 353:164-71.
5. Gold DT, Silverman SL. Compliance with osteoporosis medications: challenges for healthcare providers. Medscape Ob/Gyn & Women's Health 2005;10:1-5.
6. Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006;38:s2-6.
7. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteo Int 2004;15:1003-8.
8. McCombs JS, Thiebaud P, McLauglin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87.
9. Cummings SR. Bone density screening: a new level of evidence? [Editorial] Ann Intern Med 2005;142:217-19.
10. Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different, treatment regimens. IMAJ 2003;5:859-62.
11. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006; 119 (Suppl 1):S 12-17.
12. Christensen DB, Williams B, Goldberg HI, Martin DP, Engelberg R, LoGerfo, JP. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care 1997;35: 1164-70.
13. Penning-van Beest FJA, Goettsch WG, Erkens JA Herings RMC. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006;28:236-42.
14. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21 1453-60.
15. Brankin E, Walker M, Lynch N, Aspray T, Lis Y, Cowell W. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 2006;22:1249-56.
16. Downey TW, Foltz Sh, Boccuzzi SJ, Omar MA, Kahler KH. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. S Med J 2006;99:570-5.
17. Cramer JA, Amonkar MM, Hebborn A, et al. Bisphosphonate dosing influences treatment adherence in postmenopausal women. Osteo Int 2005; 16(Suppl. 3):s24.
18. ICDC, Ministry of Health. National Health Survey in Israel - a WHO project, European Sector. EUROHIS. 2004: publication no 237. Module A: Women's Health. August 2004.
19. Liel Y, Castel H. Incidence of osteoporotic fractures in southern Israel. Harefuah 2004;143:18-21 (Hebrew).
20. Boccuzzi SJ, Foltz SH, Omar MA, Kahler KH, Gutierrez. B. Adherence and persistence associated with the pharmacologic treatment of osteoporosis. Osteo Int 2005;16(Suppl 3):s3.
21. Remmennick LI. Preventive behaviour among recent immigrants: Russian-speaking women and cancer screening in Israel. Soc Sci Med 1999:48:1669-84.
22. Lo JC, Pressman AR, Omar MA, Ettinger R. Persistence with weekly alendronate therapy among postmenopausal women. Osteo Int 2006; 17:922-8.
23. Kern, LM, Powe NR, Levine MA, et al. Association between screening for osteoporosis and the incidence of hip fracture. Ann Intern Med 2005;142:173-81.
24. Bendlack J. HMO membership 2004-2005. National Insurance report, June 2006 (Hebrew).